Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 94

1.

Avascular necrosis in pediatric systemic lupus erythematosus: a brief report and review of the literature.

Gurion R, Tangpricha V, Yow E, Schanberg LE, McComsey GA, Robinson AB; Atherosclerosis Prevention in Pediatric Lupus Erythematosus Investigators.

Pediatr Rheumatol Online J. 2015 Apr 23;13:13. doi: 10.1186/s12969-015-0008-x.

2.

Quality Improvement Implementation: Improving Reproducibility in the Echocardiography Laboratory.

Daubert MA, Yow E, Barnhart HX, Rabineau D, Crowley AL, Douglas PS.

J Am Soc Echocardiogr. 2015 Apr 10. pii: S0894-7317(15)00180-7. doi: 10.1016/j.echo.2015.03.004. [Epub ahead of print]

PMID:
25868600
3.

Outcomes of anatomical versus functional testing for coronary artery disease.

Douglas PS, Hoffmann U, Patel MR, Mark DB, Al-Khalidi HR, Cavanaugh B, Cole J, Dolor RJ, Fordyce CB, Huang M, Khan MA, Kosinski AS, Krucoff MW, Malhotra V, Picard MH, Udelson JE, Velazquez EJ, Yow E, Cooper LS, Lee KL; PROMISE Investigators.

N Engl J Med. 2015 Apr 2;372(14):1291-300. doi: 10.1056/NEJMoa1415516. Epub 2015 Mar 14.

4.

Vitamin D status is a determinant of atorvastatin effect on carotid intima medial thickening progression rate in children with lupus: an Atherosclerosis Prevention in Pediatric Lupus Erythematosus (APPLE) substudy.

Robinson AB, Tangpricha V, Yow E, Gurion R, Schanberg LE, McComsey GA; APPLE Investigators.

Lupus Sci Med. 2014 Sep 10;1(1):e000037. doi: 10.1136/lupus-2014-000037. eCollection 2014.

5.

Vitamin D deficiency is common and associated with increased C-reactive protein in children and young adults with lupus: an Atherosclerosis Prevention in Pediatric Lupus Erythematosus substudy.

Robinson AB, Tangpricha V, Yow E, Gurion R, McComsey GA, Schanberg LE; APPLE Investigators.

Lupus Sci Med. 2014 Apr 30;1(1):e000011. doi: 10.1136/lupus-2014-000011. eCollection 2014.

6.

Randomized trial of acetylcysteine in idiopathic pulmonary fibrosis.

Idiopathic Pulmonary Fibrosis Clinical Research Network, Martinez FJ, de Andrade JA, Anstrom KJ, King TE Jr, Raghu G.

N Engl J Med. 2014 May 29;370(22):2093-101. doi: 10.1056/NEJMoa1401739. Epub 2014 May 18.

7.

Choice of agreement indices for assessing and improving measurement reproducibility in a core laboratory setting.

Barnhart HX, Yow E, Crowley AL, Daubert MA, Rabineau D, Bigelow R, Pencina M, Douglas PS.

Stat Methods Med Res. 2014 May 14. pii: 0962280214534651. [Epub ahead of print]

PMID:
24831133
8.

Anti-acid treatment and disease progression in idiopathic pulmonary fibrosis: an analysis of data from three randomised controlled trials.

Lee JS, Collard HR, Anstrom KJ, Martinez FJ, Noth I, Roberts RS, Yow E, Raghu G; IPFnet Investigators.

Lancet Respir Med. 2013 Jul;1(5):369-76. doi: 10.1016/S2213-2600(13)70105-X. Epub 2013 Jun 14.

9.

Suspected acute exacerbation of idiopathic pulmonary fibrosis as an outcome measure in clinical trials.

Collard HR, Yow E, Richeldi L, Anstrom KJ, Glazer C; IPFnet investigators.

Respir Res. 2013 Jul 13;14:73. doi: 10.1186/1465-9921-14-73.

10.

Methods of creatine kinase-MB analysis to predict mortality in patients with myocardial infarction treated with reperfusion therapy.

Lopes RD, Lokhnygina Y, Hasselblad V, Newby KL, Yow E, Granger CB, Armstrong PW, Hochman JS, Mills JS, Ruzyllo W, Mahaffey KW.

Trials. 2013 May 2;14:123. doi: 10.1186/1745-6215-14-123.

11.

Sildenafil preserves exercise capacity in patients with idiopathic pulmonary fibrosis and right-sided ventricular dysfunction.

Han MK, Bach DS, Hagan PG, Yow E, Flaherty KR, Toews GB, Anstrom KJ, Martinez FJ; IPFnet Investigators.

Chest. 2013 Jun;143(6):1699-708. doi: 10.1378/chest.12-1594.

12.

Annexin A5 anticoagulant activity in children with systemic lupus erythematosus and the association with antibodies to domain I of β2-glycoprotein I.

Wahezi DM, Ilowite NT, Wu XX, Pelkmans L, Laat B, Schanberg LE, Rand JH; Atherosclerosis Prevention in Pediatric Lupus Erythematosus Investigators.

Lupus. 2013 Jun;22(7):702-11. doi: 10.1177/0961203313490241. Epub 2013 May 20.

13.

Secondary analysis of APPLE study suggests atorvastatin may reduce atherosclerosis progression in pubertal lupus patients with higher C reactive protein.

Ardoin SP, Schanberg LE, Sandborg CI, Barnhart HX, Evans GW, Yow E, Mieszkalski KL, Ilowite NT, Eberhard A, Imundo LF, Kimura Y, Levy D, von Scheven E, Silverman E, Bowyer SL, Punaro L, Singer NG, Sherry DD, McCurdy DK, Klein-Gitelman M, Wallace C, Silver RM, Wagner-Weiner L, Higgins GC, Brunner HI, Jung L, Soep JB, Reed AM, Thompson SD; APPLE investigators.

Ann Rheum Dis. 2014 Mar;73(3):557-66. doi: 10.1136/annrheumdis-2012-202315. Epub 2013 Feb 22.

14.

Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis.

Idiopathic Pulmonary Fibrosis Clinical Research Network, Raghu G, Anstrom KJ, King TE Jr, Lasky JA, Martinez FJ.

N Engl J Med. 2012 May 24;366(21):1968-77. doi: 10.1056/NEJMoa1113354. Epub 2012 May 20.

15.

Long-term survival of patients with ischemic cardiomyopathy treated by coronary artery bypass grafting versus medical therapy.

Velazquez EJ, Williams JB, Yow E, Shaw LK, Lee KL, Phillips HR, O'Connor CM, Smith PK, Jones RH.

Ann Thorac Surg. 2012 Feb;93(2):523-30. doi: 10.1016/j.athoracsur.2011.10.064.

16.

Use of atorvastatin in systemic lupus erythematosus in children and adolescents.

Schanberg LE, Sandborg C, Barnhart HX, Ardoin SP, Yow E, Evans GW, Mieszkalski KL, Ilowite NT, Eberhard A, Imundo LF, Kimura Y, von Scheven E, Silverman E, Bowyer SL, Punaro M, Singer NG, Sherry DD, McCurdy D, Klein-Gitelman M, Wallace C, Silver R, Wagner-Weiner L, Higgins GC, Brunner HI, Jung L, Soep JB, Reed AM, Provenzale J, Thompson SD; Atherosclerosis Prevention in Pediatric Lupus Erythematosus Investigators.

Arthritis Rheum. 2012 Jan;64(1):285-96. doi: 10.1002/art.30645.

17.

Platelet activity associated with concomitant use of clopidogrel and proton pump inhibitors in children with cardiovascular disease.

Pasquali SK, Yow E, Jennings LK, Li JS.

Congenit Heart Dis. 2010 Nov-Dec;5(6):552-5. doi: 10.1111/j.1747-0803.2010.00461.x.

18.

Laboratory markers of cardiovascular risk in pediatric SLE: the APPLE baseline cohort.

Ardoin SP, Schanberg LE, Sandborg C, Yow E, Barnhart HX, Mieszkalski Kl, Ilowite NT, von Scheven E, Eberhard A, Levy DM, Kimura Y, Silverman E, Bowyer SL, Punaro L, Singer NG, Sherry DD, McCurdy D, Klein-Gitelman M, Wallace C, Silver R, Wagner-Weiner L, Higgins GC, Brunner HI, Jung LK, Imundo L, Soep JB, Reed AM; APPLE investigators.

Lupus. 2010 Oct;19(11):1315-25. doi: 10.1177/0961203310373937.

19.

A controlled trial of sildenafil in advanced idiopathic pulmonary fibrosis.

Idiopathic Pulmonary Fibrosis Clinical Research Network, Zisman DA, Schwarz M, Anstrom KJ, Collard HR, Flaherty KR, Hunninghake GW.

N Engl J Med. 2010 Aug 12;363(7):620-8. doi: 10.1056/NEJMoa1002110. Epub 2010 May 18.

20.

Metabolic syndrome is not associated with increased mortality or cardiovascular risk in nondiabetic patients with a new diagnosis of coronary artery disease.

Petersen JL, Yow E, AlJaroudi W, Shaw LK, Goyal A, McGuire DK, Peterson ED, Harrington RA.

Circ Cardiovasc Qual Outcomes. 2010 Mar;3(2):165-72. doi: 10.1161/CIRCOUTCOMES.109.864447. Epub 2010 Feb 23.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk